{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:40:52Z","timestamp":1766130052857,"version":"3.48.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"S\u00f8ster og Verner Lipperts fond"},{"name":"Inge og Asker Larsens Fond","award":["039252-0005 seb\/ruh"],"award-info":[{"award-number":["039252-0005 seb\/ruh"]}]},{"DOI":"10.13039\/501100005747","name":"A.P. M\u00f8ller Fonden","doi-asserted-by":"crossref","award":["L-2022-00060"],"award-info":[{"award-number":["L-2022-00060"]}],"id":[{"id":"10.13039\/501100005747","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Andersen-Isted fond"},{"DOI":"10.13039\/501100010347","name":"Fabrikant Einar Willumsens Mindelegat","doi-asserted-by":"publisher","award":["J. nr. 500028"],"award-info":[{"award-number":["J. nr. 500028"]}],"id":[{"id":"10.13039\/501100010347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Agnethe L\u00f8vgreens Fond"},{"DOI":"10.13039\/501100007438","name":"Familien Hede Nielsens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007438","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Frimodt-Heinike Fonden"},{"DOI":"10.13039\/501100021817","name":"Knud og Edith Eriksens Mindefond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021817","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R302-A17420"],"award-info":[{"award-number":["R302-A17420"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04843-z","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:38:03Z","timestamp":1766129883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetic comparison of cisplatin administration via HIPEC and intravenous infusion in a porcine model"],"prefix":"10.1007","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7255-9557","authenticated-orcid":false,"given":"Christina","family":"Harlev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5164-5197","authenticated-orcid":false,"given":"Elisabeth Krogsgaard","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7215-8323","authenticated-orcid":false,"given":"Mats","family":"Bue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1424-6170","authenticated-orcid":false,"given":"Lone Kjeld","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6453-9681","authenticated-orcid":false,"given":"Johanne Gade","family":"Lille\u00f8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6305-8563","authenticated-orcid":false,"given":"Anne Vibeke","family":"Schmedes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4742-4076","authenticated-orcid":false,"given":"Bo Martin","family":"Bibby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4530-2075","authenticated-orcid":false,"given":"Maiken","family":"Stilling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"4843_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092230","author":"J Huang","year":"2022","unstructured":"Huang J et al (2022) Worldwide burden, risk factors, and temporal trends of ovarian cancer: a global study. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14092230","journal-title":"Cancers (Basel)"},{"key":"4843_CR2","doi-asserted-by":"publisher","unstructured":"Timmermans M, Sonke GS, Van de Vijver KK, van der Aa MA, Kruitwagen R (Jan 2018) No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands, (in eng). Eur J Cancer 88:31\u201337. https:\/\/doi.org\/10.1016\/j.ejca.2017.10.030","DOI":"10.1016\/j.ejca.2017.10.030"},{"key":"4843_CR3","doi-asserted-by":"publisher","unstructured":"Pignata S, S CC, Du Bois A, Harter P, Heitz F (2017) Treatment of recurrent ovarian cancer, (in eng), Ann Oncol, vol. 28, no. suppl_8, pp. viii51-viii56, Nov 1 https:\/\/doi.org\/10.1093\/annonc\/mdx441","DOI":"10.1093\/annonc\/mdx441"},{"issue":"25","key":"4843_CR4","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1200\/jco.22.02766","volume":"41","author":"RF Ozols","year":"2023","unstructured":"Ozols RF et al (2023) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol 41(25):4077\u20134083. https:\/\/doi.org\/10.1200\/jco.22.02766","journal-title":"J Clin Oncol"},{"issue":"6","key":"4843_CR5","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.hoc.2018.07.010","volume":"32","author":"B Orr","year":"2018","unstructured":"Orr B, Edwards RP (2018) Diagnosis and treatment of ovarian cancer. Hematol Oncol Clin North Am 32(6):943\u2013964. https:\/\/doi.org\/10.1016\/j.hoc.2018.07.010","journal-title":"Hematol Oncol Clin North Am"},{"key":"4843_CR6","doi-asserted-by":"publisher","unstructured":"de Bree E, Michelakis D, Stamatiou D, Romanos J, Zoras O (2017) Pharmacological principles of intraperitoneal and bidirectional chemotherapy, (in eng), Pleura Peritoneum, vol. 2, no. 2, pp. 47\u201362, Jun 1 https:\/\/doi.org\/10.1515\/pp-2017-0010","DOI":"10.1515\/pp-2017-0010"},{"key":"4843_CR7","doi-asserted-by":"publisher","unstructured":"Jacquet P, Sugarbaker PH (1996) Peritoneal-plasma barrier, (in eng), Cancer Treat Res, vol. 82, pp. 53\u201363. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_4","DOI":"10.1007\/978-1-4613-1247-5_4"},{"key":"4843_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-1-4613-1247-5_3","volume":"82","author":"PH Sugarbaker","year":"1996","unstructured":"Sugarbaker PH, Stuart OA, Vidal-Jove J, Pessagno AM, DeBruijn EA (1996) Pharmacokinetics of the peritoneal-plasma barrier after systemic mitomycin C administration, (in eng). Cancer Treat Res 82:41\u201352. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_3","journal-title":"Cancer Treat Res"},{"issue":"2","key":"4843_CR9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ygyno.2015.06.012","volume":"139","author":"P Cascales-Campos","year":"2015","unstructured":"Cascales-Campos P, Gil J, Feliciangeli E, Parrilla P (2015) Hipec in ovarian cancer: treatment of a new era or is it the end of the pipeline? Gynecol Oncol 139(2):363\u2013368. https:\/\/doi.org\/10.1016\/j.ygyno.2015.06.012","journal-title":"Gynecol Oncol"},{"key":"4843_CR10","doi-asserted-by":"publisher","unstructured":"Zivanovic O et al HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer, (in eng). Int J Cancer, 136, 3, pp. 699\u2013708, Feb 1 2015, https:\/\/doi.org\/10.1002\/ijc.29011","DOI":"10.1002\/ijc.29011"},{"issue":"10","key":"4843_CR11","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/s1470-2045(23)00396-0","volume":"24","author":"SL Aronson","year":"2023","unstructured":"Aronson SL et al (2023) Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial. Lancet Oncol 24(10):1109\u20131118. https:\/\/doi.org\/10.1016\/s1470-2045(23)00396-0","journal-title":"Lancet Oncol"},{"issue":"5","key":"4843_CR12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","volume":"157","author":"MC Lim","year":"2022","unstructured":"Lim MC et al (2022) Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer. JAMA Surg 157(5):374\u2013383. https:\/\/doi.org\/10.1001\/jamasurg.2022.0143","journal-title":"JAMA Surg"},{"issue":"11","key":"4843_CR13","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamasurg.2023.3944","volume":"158","author":"JY Lee","year":"2023","unstructured":"Lee JY et al (2023) Hyperthermic intraperitoneal chemotherapy after interval cytoreductive surgery for patients with advanced-stage ovarian cancer who had received neoadjuvant chemotherapy. JAMA Surg 158(11):1133\u20131140. https:\/\/doi.org\/10.1001\/jamasurg.2023.3944","journal-title":"JAMA Surg"},{"issue":"13","key":"4843_CR14","doi-asserted-by":"publisher","first-page":"9098","DOI":"10.1245\/s10434-021-10193-w","volume":"28","author":"A Bhatt","year":"2021","unstructured":"Bhatt A et al (2021) Hipec methodology and regimens: the need for an expert consensus. Ann Surg Oncol 28(13):9098\u20139113. https:\/\/doi.org\/10.1245\/s10434-021-10193-w","journal-title":"Ann Surg Oncol"},{"issue":"20","key":"4843_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25204733","volume":"25","author":"G Kireeva","year":"2020","unstructured":"Kireeva G et al (2020) Modeling of chemoperfusion vs. intravenous administration of Cisplatin in Wistar rats: adsorption and tissue distribution. Molecules 25(20):4733","journal-title":"Molecules"},{"key":"4843_CR16","doi-asserted-by":"publisher","unstructured":"Cashin PH, Ehrsson H, Wallin I, Nygren P, Mahteme H (2013) Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis, (in eng), Eur J Clin Pharmacol, vol. 69, no. 3, pp. 533\u2009\u2013\u200940, Mar https:\/\/doi.org\/10.1007\/s00228-012-1405-4","DOI":"10.1007\/s00228-012-1405-4"},{"key":"4843_CR17","doi-asserted-by":"crossref","unstructured":"Kim YJ, Lee HM, Lee GE, Yoo JH, Lee HJ, Rhie SJ (2024) Optimizing Outcomes: Bevacizumab with Carboplatin and Paclitaxel in 5110 Ovarian Cancer Patients\u2014A Systematic Review and Meta-Analysis, Pharmaceuticals, vol. 17, no. 8, p. 1095, [Online]. Available: https:\/\/www.mdpi.com\/1424-8247\/17\/8\/1095","DOI":"10.3390\/ph17081095"},{"issue":"14","key":"4843_CR18","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1158\/0008-5472.Can-16-2871","volume":"77","author":"S Chakrabarti","year":"2017","unstructured":"Chakrabarti S, Michor F (2017) Pharmacokinetics and drug interactions determine optimum combination strategies in computational models of cancer evolution. Cancer Res 77(14):3908\u20133921. https:\/\/doi.org\/10.1158\/0008-5472.Can-16-2871","journal-title":"Cancer Res"},{"key":"4843_CR19","doi-asserted-by":"publisher","unstructured":"Harlev C et al (2025) Dynamic assessment of local abdominal tissue concentrations of Cisplatin during a HIPEC procedure: insights from a porcine model. Ann Surg Oncol. https:\/\/doi.org\/10.1245\/s10434-025-17000-w","DOI":"10.1245\/s10434-025-17000-w"},{"key":"4843_CR20","doi-asserted-by":"publisher","unstructured":"Harlev C, Intraperitoneal Chemotherapy On Abdominal Tissue Concentrations Of Cisplatin (2025) The Role Of Hyperthermia In : Insights From A Porcine Model, International Journal of Gynecological Cancer, vol. 35, no. 2. https:\/\/doi.org\/10.1016\/j.ijgc.2024.100123","DOI":"10.1016\/j.ijgc.2024.100123"},{"issue":"6","key":"4843_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000412","volume":"8","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8(6):e1000412. https:\/\/doi.org\/10.1371\/journal.pbio.1000412","journal-title":"PLoS Biol"},{"issue":"5","key":"4843_CR22","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1208\/s12248-017-0108-2","volume":"19","author":"M Hammarlund-Udenaes","year":"2017","unstructured":"Hammarlund-Udenaes M (2017) Microdialysis as an important technique in systems pharmacology-a historical and methodological review. AAPS J 19(5):1294\u20131303. https:\/\/doi.org\/10.1208\/s12248-017-0108-2","journal-title":"AAPS J"},{"key":"4843_CR23","doi-asserted-by":"publisher","unstructured":"Schmedes AV et al (Feb 3 2024) Analysis of free cisplatin in microdialysates and plasma ultrafiltrate by liquid chromatography-tandem mass spectrometry, (in eng). J Chromatogr B Analyt Technol Biomed Life Sci 1235:124040. https:\/\/doi.org\/10.1016\/j.jchromb.2024.124040","DOI":"10.1016\/j.jchromb.2024.124040"},{"key":"4843_CR24","doi-asserted-by":"publisher","unstructured":"Zhang T et al (2024) Pharmacokinetics of cisplatin in the systemic versus hyperthermic intrathoracic or intraperitoneal chemotherapy, (in eng), Cancer Chemother Pharmacol, vol. 95, no. 1, p. 13, Dec 26 https:\/\/doi.org\/10.1007\/s00280-024-04727-8","DOI":"10.1007\/s00280-024-04727-8"},{"issue":"3","key":"4843_CR25","first-page":"878","volume":"8","author":"IF Tannock","year":"2002","unstructured":"Tannock IF, Lee CM, Tunggal JK, Cowan DSM, Egorin MJ (2002) Limited penetration of anticancer drugs through tumor tissue: A potential cause of resistance of solid tumors to Chemotherapy1. Clin Cancer Res 8(3):878\u2013884","journal-title":"Clin Cancer Res"},{"key":"4843_CR26","doi-asserted-by":"publisher","unstructured":"Toutain PL, Ferran A, Bousquet-M\u00e9lou A (2010) Species differences in pharmacokinetics and pharmacodynamics, (in eng), Handb Exp Pharmacol, no. 199, pp. 19\u201348. https:\/\/doi.org\/10.1007\/978-3-642-10324-7_2","DOI":"10.1007\/978-3-642-10324-7_2"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04843-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04843-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04843-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:38:05Z","timestamp":1766129885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04843-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4843"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04843-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}